Acta neurologica Belgica · 2026
Diagnostic accuracy of CSF and plasma pTau-181, pTau-217, and pTau-231 for Alzheimer's disease: a diagnostic meta-analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mohammed Hazem E, Haseeb Mohamed E, Nasser Mohamed, Hanen George, Abdelkader Mohamed Salem, Yaser Hatem, Yaser Shehab, Samir Ahmed, Arafeh Yusra, Wagdy Mohamed, Darwish Mohamed Khalafalla
Аннотация
BACKGROUND: Alzheimer's disease (AD) remains the most common cause of dementia worldwide, yet achieving an accurate early diagnosis continues to pose a major challenge. Recent advances highlight phosphorylated tau (pTau) isoforms-pTau-181, pTau-217, and pTau-231-detected in cerebrospinal fluid (CSF) and plasma as promising biomarkers capable of distinguishing AD from non-Alzheimer's dementias and cognitively healthy individuals (HC). This study aimed to comprehensively assess the diagnostic accuracy of these pTau isoforms through a systematic review and diagnostic meta-analysis.
METHODS: Following PRISMA 2020 guidelines and PROSPERO registration (CRD42025632278), we performed a systematic search of PubMed, Scopus, and Web of Science databases through September 2025. Eligible studies evaluated the diagnostic performance of pTau-181, pTau-217, or pTau-231 in CSF or plasma using established AD reference standards. Pooled sensitivity, specificity, diagnostic odds ratio (DOR), and area under the curve (AUC) were calculated using random-effects models. Clinical applicability was assessed via Fagan's nomogram, and publication bias was examined using Deeks' funnel plot asymmetry test.
RESULTS: Forty-eight studies encompassing diverse international cohorts met inclusion criteria. In differentiating AD from HC, CSF pTau-217 demonstrated the highest diagnostic precision (sensitivity = 0.95; specificity = 0.91), outperforming pTau-181 and pTau-231 (AUC = 0.90 each). Plasma biomarkers also exhibited strong diagnostic value: plasma pTau-181 achieved sensitivity of 0.88, specificity of 0.81, and AUC of 0.91, while plasma pTau-231 displayed sensitivity of 0.84, specificity of 0.87, and AUC of 0.86, with low interstudy heterogeneity. Comparative analyses confirmed significantly higher pTau concentrations in AD relative to both non-AD dementias and healthy controls. The overall certainty of evidence ranged from moderate to high, supporting the robustness of these findings.
CONCLUSIONS: This meta-analysis supports the strong diagnostic performance of pTau isoforms, particularly CSF pTau-217, in distinguishing Alzheimer's disease from healthy controls and non-Alzheimer's dementias. However, evidence for CSF pTau-217 is limited and largely derived from limited number of studies. Although plasma pTau-181 and pTau-231 show promising diagnostic accuracy, further real-world validation, assay standardization, and assessment within established diagnostic pathways are needed.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: Following PRISMA 2020 guidelines and PROSPERO registration (CRD42025632278), we performed a systematic search of PubMed, Scopus, and Web of Science databases through September 2025. Eligible studies evaluated the diagnostic performance of pTau-181, pTau-217, or pTau-231 in CSF or plasma using established AD reference standards. Pooled sensitivity, specificity, diagnostic odds ratio (DOR), and area under the curve (AUC) were calculated using random-effects models. Clinical applicability was assessed via Fagan's nomogram, and publication bias was examined using Deeks' funnel plot asymmetry test.
RESULTS: Forty-eight studies encompassing diverse international cohorts met inclusion criteria. In differentiating AD from HC, CSF pTau-217 demonstrated the highest diagnostic precision (sensitivity = 0.95; specificity = 0.91), outperforming pTau-181 and pTau-231 (AUC = 0.90 each). Plasma biomarkers also exhibited strong diagnostic value: plasma pTau-181 achieved sensitivity of 0.88, specificity of 0.81, and AUC of 0.91, while plasma pTau-231 displayed sensitivity of 0.84, specificity of 0.87, and AUC of 0.86, with low interstudy heterogeneity. Comparative analyses confirmed significantly higher pTau concentrations in AD relative to both non-AD dementias and healthy controls. The overall certainty of evidence ranged from moderate to high, supporting the robustness of these findings.
CONCLUSIONS: This meta-analysis supports the strong diagnostic performance of pTau isoforms, particularly CSF pTau-217, in distinguishing Alzheimer's disease from healthy controls and non-Alzheimer's dementias. However, evidence for CSF pTau-217 is limited and largely derived from limited number of studies. Although plasma pTau-181 and pTau-231 show promising diagnostic accuracy, further real-world validation, assay standardization, and assessment within established diagnostic pathways are needed.
CLINICAL TRIAL NUMBER: Not applicable.